EICHORCondition: Pancreatic Cancer · Pancreatic Carcinoma · Pancreatic Ductal Adenocarcinoma · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to find out how effective and safe glipizide is for lowering blood sugar in people with pancreatic cancer.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | — |
| Memorial Sloan Kettering Monmouth (Limited protocol activities) | Middletown, New Jersey, United States | — |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | — |
| Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) | Commack, New York, United States | — |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale, New York, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06168812